Frontiers in Immunology (Sep 2022)
Common variable immunodeficiency in two kindreds with heterogeneous phenotypes caused by novel heterozygous NFKB1 mutations
- Frederik Staels,
- Frederik Staels,
- Kerstin De Keukeleere,
- Kerstin De Keukeleere,
- Matias Kinnunen,
- Salla Keskitalo,
- Flaminia Lorenzetti,
- Flaminia Lorenzetti,
- Michiel Vanmeert,
- Teresa Prezzemolo,
- Emanuela Pasciuto,
- Emanuela Pasciuto,
- Eveline Lescrinier,
- Xavier Bossuyt,
- Margaux Gerbaux,
- Mathijs Willemsen,
- Julika Neumann,
- Sien Van Loo,
- Anniek Corveleyn,
- Karen Willekens,
- Ingeborg Stalmans,
- Isabelle Meyts,
- Isabelle Meyts,
- Adrian Liston,
- Adrian Liston,
- Stephanie Humblet-Baron,
- Mikko Seppänen,
- Markku Varjosalo,
- Rik Schrijvers,
- Rik Schrijvers
Affiliations
- Frederik Staels
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Frederik Staels
- Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium
- Kerstin De Keukeleere
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Kerstin De Keukeleere
- Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium
- Matias Kinnunen
- Molecular Systems Biology Research Group and Proteomics Unit, Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
- Salla Keskitalo
- Molecular Systems Biology Research Group and Proteomics Unit, Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
- Flaminia Lorenzetti
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Flaminia Lorenzetti
- Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium
- Michiel Vanmeert
- Department of Pharmacy and Pharmacology, Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
- Teresa Prezzemolo
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Emanuela Pasciuto
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Emanuela Pasciuto
- Department of Neurosciences, Research Group of Molecular Neurobiology, VIB-KU Leuven, Leuven, Belgium
- Eveline Lescrinier
- Department of Pharmacy and Pharmacology, Medicinal Chemistry, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium
- Xavier Bossuyt
- Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium
- Margaux Gerbaux
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Mathijs Willemsen
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Julika Neumann
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Sien Van Loo
- Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
- Anniek Corveleyn
- Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
- Karen Willekens
- Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
- Ingeborg Stalmans
- Department of Neurosciences, Research Group of Ophthalmology, KU Leuven, Leuven, Belgium
- Isabelle Meyts
- Department of Microbiology, Immunology and Transplantation, Laboratory for Inborn Errors of Immunity, KU Leuven, Leuven, Belgium
- Isabelle Meyts
- 0Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium
- Adrian Liston
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Adrian Liston
- 1Laboratory of Lymphocyte Signaling and Development, Babraham Institute, Cambridge, United Kingdom
- Stephanie Humblet-Baron
- Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunology, KU Leuven, Leuven, Belgium
- Mikko Seppänen
- 2Rare Disease and Pediatric Research Centers, New Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- Markku Varjosalo
- Molecular Systems Biology Research Group and Proteomics Unit, Institute of Biotechnology, HiLIFE Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
- Rik Schrijvers
- Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium
- Rik Schrijvers
- 3Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium
- DOI
- https://doi.org/10.3389/fimmu.2022.973543
- Journal volume & issue
-
Vol. 13
Abstract
NFKB1 haploinsufficiengcy was first described in 2015 in three families with common variable immunodeficiency (CVID), presenting heterogeneously with symptoms of increased infectious susceptibility, skin lesions, malignant lymphoproliferation and autoimmunity. The described mutations all led to a rapid degradation of the mutant protein, resulting in a p50 haploinsufficient state. Since then, more than 50 other mutations have been reported, located throughout different domains of NFKB1 with the majority situated in the N-terminal Rel homology domain (RHD). The clinical spectrum has also expanded with possible disease manifestations in almost any organ system. In silico prediction tools are often used to estimate the pathogenicity of NFKB1 variants but to prove causality between disease and genetic findings, further downstream functional validation is required. In this report, we studied 2 families with CVID and two novel variants in NFKB1 (c.1638-2A>G and c.787G>C). Both mutations affected mRNA and/or protein expression of NFKB1 and resulted in excessive NLRP3 inflammasome activation in patient macrophages and upregulated interferon stimulated gene expression. Protein-protein interaction analysis demonstrated a loss of interaction with NFKB1 interaction partners for the p.V263L mutation. In conclusion, we proved pathogenicity of two novel variants in NFKB1 in two families with CVID characterized by variable and incomplete penetrance.
Keywords